PRE0109

Breast

Indiana University (IU)

• Eskenazi Hospital
• IU Health North/ Schwarz Cancer Center
• Indiana University Hospital / IU Simon Cancer Center
• Spring Mill Medical Center

• Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
  Gnant M;Dueck AC;Frantal S;Martin M;Burstein HJ;Greil R;Fox P;Wolff AC;Chan A;Winer EP;Pfeiler G;Miller KD;Colleoni M;Suga JM;Rubovsky G;Bliss JM;Mayer IA;Singer CF;Nowecki Z;Hahn O;Thomson J;Wolmark N;Amillano K;Rugo HS;Steger GG;Hernando Fernández de Aránguiz B;Haddad TC;Perelló A;Bellet M;Fohler H;Metzger Filho O;Jallitsch-Halper A;Solomon K;Schurmans C;Theall KP;Lu DR;Tenner K;Fesl C;DeMichele A;Mayer EL; ;
• Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
  Mayer EL;Dueck AC;Martin M;Rubovszky G;Burstein HJ;Bellet-Ezquerra M;Miller KD;Zdenkowski N;Winer EP;Pfeiler G;Goetz M;Ruiz-Borrego M;Anderson D;Nowecki Z;Loibl S;Moulder S;Ring A;Fitzal F;Traina T;Chan A;Rugo HS;Lemieux J;Henao F;Lyss A;Antolin Novoa S;Wolff AC;Vetter M;Egle D;Morris PG;Mamounas EP;Gil-Gil MJ;Prat A;Fohler H;Metzger Filho O;Schwarz M;DuFrane C;Fumagalli D;Theall KP;Lu DR;Bartlett CH;Koehler M;Fesl C;DeMichele A;Gnant M;
• Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
  Mayer EL;Fesl C;Hlauschek D;Garcia-Estevez L;Burstein HJ;Zdenkowski N;Wette V;Miller KD;Balic M;Mayer IA;Cameron D;Winer EP;Ponce Lorenzo JJ;Lake D;Pristauz-Telsnigg G;Haddad TC;Shepherd L;Iwata H;Goetz M;Cardoso F;Traina TA;Sabanathan D;Breitenstein U;Ackerl K;Metzger Filho O;Zehetner K;Solomon K;El-Abed S;Theall KP;Lu DR;Dueck A;Gnant M;DeMichele A;
• Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
  Diéras V;Rugo HS;Schnell P;Gelmon K;Cristofanilli M;Loi S;Colleoni M;Lu DR;Mori A;Gauthier E;Huang Bartlett C;Slamon DJ;Turner NC;Finn RS;
• Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
  Pfeiler G;Hlauschek D;Mayer EL;Deutschmann C;Kacerovsky-Strobl S;Martin M;Meisel JL;Zdenkowski N;Loibl S;Balic M;Park H;Prat A;Isaacs C;Bajetta E;Balko JM;Bellet-Ezquerra M;Bliss J;Burstein H;Cardoso F;Fohler H;Foukakis T;Gelmon KA;Goetz M;Haddad TC;Iwata H;Jassem J;Lee SC;Linderholm B;Los M;Mamounas EP;Miller KD;Morris PG;Munzone E;Gal-Yam EN;Ring A;Shepherd L;Singer C;Thomssen C;Tseng LM;Valagussa P;Winer EP;Wolff AC;Zoppoli G;Machacek-Link J;Schurmans C;Huang X;Gauthier E;Fesl C;Dueck AC;DeMichele A;Gnant M; ;
• Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
  DeMichele A;Dueck AC;Hlauschek D;Martin M;Burstein H;Pfeiler G;Zdenkowski N;Wolff A;Bellet-Ezquerra M;Winer E;Balic M;Miller K;Colleoni M;Lake D;Rubovsky G;Cameron D;Balko J;Singer CF;Nowecki Z;Iwata H;Wolmark N;Parraga KA;Rugo H;Steger GG;Traina T;Werutsky G;Czajkowska D;Metzger O;El-Abed S;Theall KP;Lu RD;O'Brien P;Fesl C;Mayer E;Gnant M;
• Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
  Shinn E;Zahrieh D;DeMichele A;Zdenkowski N;Lemieux J;Mao J;Bjelic-Radisic V;Naughton MJ;Pfeiler G;Gelmon K;Balko JM;Egle D;Zoppoli G;Traina T;Jimenez MM;Novoa SA;Haddad T;Chan A;Ring A;Wolff A;Symmans WF;Ponce Lorenzo J;Sabanathan D;Burstein HJ;Nowecki ZI;Pristauz-Telsnigg G;Brufsky A;Bellet-Ezquerra M;Foukakis T;Novik Y;Rubovszky G;Singer CF;Muehlbacher K;Filho OM;Goulioti T;Law E;Partridge AH;Carey LA;Zoroufy A;Hlauschek D;Fesl C;Mayer EL;Gnant M;